Look up one drug

Reason for Use code 526 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Approvals will only allow for standard dosing for Taltz 160mg at week 0, followed by 80mg subcutaneously at weeks 2, 4, 6, 8, 10, and 12, and then 80mg every 4 weeks. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent. Note 1: Definiton of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least 50% reduction in PASI, AND - at least 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Ixekizumab Brand(s): Taltz DOSAGE FORM/ STRENGTH: 80 mg/mL Autoinjector or 80 mg/mL Syringe for subcutaneous injection Effective date: March 4, 2019 Secukinumab Brand(s): Cosentyx DOSAGE FORM/ STRENGTH: 150 mg/mL prefilled syringe and 150 mg/mL prefilled pen Effective date: March 6, 2018 Psoriatic Arthritis Initiation Criteria: For the treatment of psoriatic arthritis (PsA) in patients who have: Severe active disease (≥ 5 swollen joints and radiographic evidence of psoriatic arthritis) despite treatment with methotrexate (20 mg/week) for at least 3 months and one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months. If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20 mg/day) or sulfasalazine (1 g twice daily) for at least 3 months is required. Details of contraindications and intolerances must also be provided. Duration of Approval: 1 Year Renewals will be considered for patients with objective evidence of at least a 20% reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For renewals beyond the second year, objective evidence of preservation of treatment effect must be provided. Duration of Approval of first renewal: 1 Year Duration of Approval: Second and subsequent renewals are 2 years Recommended Dose: The planned dosing regimen for the requested biologic should be provided. 411 Ixekizumab: Ixekizumab for the treatment of psoriatic arthritis (PsA) patients or those with PsA and coexistent mild plaque psoriasis: 160 mg (two 80 mg injections) sc at Week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to severe plaque psoriasis, you may wish to refer to the ODB formulary for access upon meeting the Limited Use Criteria for Plaque psoriasis. (EAP authorization would not be required). Dose recommended for such patients is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 6 doses (i.e. weeks 2, 4, 6, 8, 10, and 12), then 80 mg every 4 weeks thereafter. Ixekizumab may be used alone or in combination with a conventional DMARD (e.g. methotrexate) Secukinumab: Secukinumab for the treatment of psoriatic arthritis 150mg sc at weeks 0, 1, 2, and 3 followed by monthly maintenance dosing starting at week 4. If a patient is an anti-TNF alpha inadequate responder and continues to have active psoriatic arthritis, consider using the 300 mg sc dose. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis (i.e. 300 mg sc at weeks 0, 1, 2, and 3, followed by monthly maintenance dosing starting at week 4) 412 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 411, record 242, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Taltz · DIN 02455102 Manufacturer: Eli Lilly Canada Inc.; listing date 2018-03-29 Health Canada: Marketed since 2023-03-20 · brand TALTZ · ATC L04AC13 IXEKIZUMAB · form Solution · route Subcutaneous · ingredients IXEKIZUMAB 80 MG/ML · company Eli lilly canada inc · schedule Schedule d, Prescription

DIN 02455102: Taltz Raw flags: sec12=Y, sec3=Y Item: 843600101; group id 865; item number 2092; lccId 00300; manufacturer id LIL Source form: Inj Sol-Pref Autoinj; strength: 80mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1976.6400; ministry $1976.6400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455102 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94193

Shortage status: resolved shortage (ended 2025-02-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455102

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 526 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Approvals will only allow for standard dosing for Taltz 160mg at week 0, followed by 80mg subcutaneously at weeks 2, 4, 6, 8, 10, and 12, and then 80mg every 4 weeks. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent. Note 1: Definiton of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least 50% reduction in PASI, AND - at least 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Ixekizumab Brand(s): Taltz DOSAGE FORM/ STRENGTH: 80 mg/mL Autoinjector or 80 mg/mL Syringe for subcutaneous injection Effective date: March 4, 2019 Secukinumab Brand(s): Cosentyx DOSAGE FORM/ STRENGTH: 150 mg/mL prefilled syringe and 150 mg/mL prefilled pen Effective date: March 6, 2018 Psoriatic Arthritis Initiation Criteria: For the treatment of psoriatic arthritis (PsA) in patients who have: Severe active disease (≥ 5 swollen joints and radiographic evidence of psoriatic arthritis) despite treatment with methotrexate (20 mg/week) for at least 3 months and one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months. If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20 mg/day) or sulfasalazine (1 g twice daily) for at least 3 months is required. Details of contraindications and intolerances must also be provided. Duration of Approval: 1 Year Renewals will be considered for patients with objective evidence of at least a 20% reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For renewals beyond the second year, objective evidence of preservation of treatment effect must be provided. Duration of Approval of first renewal: 1 Year Duration of Approval: Second and subsequent renewals are 2 years Recommended Dose: The planned dosing regimen for the requested biologic should be provided. 411 Ixekizumab: Ixekizumab for the treatment of psoriatic arthritis (PsA) patients or those with PsA and coexistent mild plaque psoriasis: 160 mg (two 80 mg injections) sc at Week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to severe plaque psoriasis, you may wish to refer to the ODB formulary for access upon meeting the Limited Use Criteria for Plaque psoriasis. (EAP authorization would not be required). Dose recommended for such patients is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 6 doses (i.e. weeks 2, 4, 6, 8, 10, and 12), then 80 mg every 4 weeks thereafter. Ixekizumab may be used alone or in combination with a conventional DMARD (e.g. methotrexate) Secukinumab: Secukinumab for the treatment of psoriatic arthritis 150mg sc at weeks 0, 1, 2, and 3 followed by monthly maintenance dosing starting at week 4. If a patient is an anti-TNF alpha inadequate responder and continues to have active psoriatic arthritis, consider using the 300 mg sc dose. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis (i.e. 300 mg sc at weeks 0, 1, 2, and 3, followed by monthly maintenance dosing starting at week 4) 412 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 411, record 242, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Taltz · DIN 02455110 Manufacturer: Eli Lilly Canada Inc.; listing date 2018-03-29 Health Canada: Marketed since 2023-04-12 · brand TALTZ · ATC L04AC13 IXEKIZUMAB · form Solution · route Subcutaneous · ingredients IXEKIZUMAB 80 MG/ML · company Eli lilly canada inc · schedule Schedule d, Prescription

DIN 02455110: Taltz Raw flags: sec12=Y, sec3=Y Item: 843600102; group id 865; item number 2093; lccId 00300; manufacturer id LIL Source form: Inj Sol-Pref Syr; strength: 80mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1990.1100; ministry $1990.1100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455110 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94194

Shortage status: resolved shortage (ended 2022-06-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02455110

Shortage record checked 2026-09-13T08:10:21.292534+00:00